IMMUNOHISTOCHEMICAL EVALUATION BEFORE AND AFTER NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER

INABA, L. A. (Instituto do Câncer Dr. Arnaldo Vieira de Carvalho), RODRIGUES, F. F. O. (Instituto do Câncer Dr. Arnaldo Vieira de Carvalho), BASTOS, E. A. (Instituto do Câncer Dr. Arnaldo Vieira de Carvalho), ARIAS, V. E. A. (Instituto do Câncer Dr. Arnal

Instituto do Câncer Dr. Arnaldo Vieira de Carvalho (ICAVC)To evaluate the immunohistochemical markers in biopsies and surgical specimens of patients with breast cancer before and after neoadjuvant chemotherapy (NACT). A retrospective database analysis from our service in patients with breast cancer treated at our institution (ICAVC) during 08/31/2006 and 01/10/2010 with follow up until 01/12/2016. A total of 106 patients with invasive breast cancer were included in the study, and 32 (30,2%) received neoadjuvant chemotherapy based on anthracycline and taxane. We observed changes in immunohistochemical markers in 31.25% of the total number of patients submitted to NACT; 7% in the subgroup of patients luminal A, 20% in the triple negative, 71% luminal-Her and a 100% of the patients luminal B. Changes in immunohistochemical markers before and after NACT occurred in 31,25% of our patients, maybe because of cytotoxic-induced morphologic alterations by the therapy or clonal selection but is still important to know once the breast cancer subtype will influence the treatment plans for the patient.breast cancer, immunohistochemical markers, neoadjuvant chemotherapy

Return